HL

Hewmun Lau

Principal at Broadview Ventures Inc

Greater Boston

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Principal

    2019

  • Principal

    2019

    Responsible for the day-to-day investment activities at Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement. Broadview is a mission-driven fund whose primary investment goal is to improve human health in the areas of cardiovascular disease and stroke. With 37 such investments since 2008, Broadview has considerable experience in the seed/early-stage space.

  • Board Observer

    2020

    Antag Therapeutics is a Copenhagen-based preclinical stage biotechnology company focused on developing therapies for dietary-related metabolic diseases. The company’s current lead therapy is a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist for inducing weight loss in obese patients with Type-2 Diabetes.

  • Board Observer

    2020

    Basking Biosciences, Inc. is developing the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS). Basking is focused on exploiting the properties of RNA biology to develop aptamers with high affinity and specificity against proteins involved in coagulation and hemostasis.

2020 - 2021

  • Board Observer

    2020 - 2021

    Renovacor is a preclinical stage biotechnology company whose mission is to develop improved therapies for genetically derived cardiovascular diseases. The company is currently developing a gene therapy for a rare, familial form of dilated cardiomyopathy due to mutation in the BAG3 gene.

2015 - 2019

  • Director of Corporate Development

    2018 - 2019

  • Associate Director, New Product Planning and Business Development

    2017 - 2018

  • Senior Manager, Commercial Analytics - ONIVYDE

    2015 - 2017

    - Play key role in building commercial analytic capabilities for Merrimack's first product launch in oncology - Analytics lead for Northeast and Southeast Regions, act as strategic thought partner with Field to develop actionable business recommendations in order to drive ONIVYDE adoption - Supported cross-functional teams in Marketing, Product Availability and Market Access, Commercial IT, among others, in critical business decision-making, Communicate key findings to a broad range of key stakeholders

2012 - 2015

  • Senior Consultant (Life Sciences Practice)

    2012 - 2015

    Strategic life science consultant with experience across multiple therapeutic areas and project types, including: - Commercial opportunity assessments and forecasting - New product launch planning - Competitive assessments - BD&L opportunity assessments Skills include primary and secondary market research, forecasting, project management

2011 - 2011

  • Summer Associate (Life Sciences Practice)

    2011 - 2011

  • Summer Intern

    2010 - 2010

    Business Development

2007 - 2009

  • Research Associate

    2007 - 2009

    Laboratory of Genetic Neuropharmacology